Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Vir Biotechnology Jumped 12% in May

By Brian Orelli, PhD – Jun 8, 2020 at 1:06PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Preclinical data for its COVID-19 treatment looked promising.

What happened

Shares of Vir Biotechnology (VIR 2.68%) rose 12% in May, according to data provided by S&P Global Market Intelligence, after the biotech published preclinical data in the journal Nature on S309, a monoclonal antibody that appears to target SARS-CoV-2, the novel coronavirus that causes COVID-19.

So what

The S309 antibody was originally isolated from a patient who recovered from severe acute respiratory syndrome (SARS) in 2003, but it appears that the structure of coronavirus responsible for SARS is close enough to that of the coronavirus that causes COVID-19 that the antibody can bind to both.

Vir is developing two treatments -- VIR-7831 and VIR-7832 -- based on the S309 antibody in collaboration with GlaxoSmithKline (GSK -0.56%). VIR-7831 was engineered to last longer in the body, while VIR-7832 includes that change plus one that may give it the ability to function as a T-cell vaccine.

Patient and doctor behind a caution outbreak alert sign

Image source: Getty Images.

Now what

Vir and GlaxoSmithKline are planning on starting clinical trials for the antibodies this summer. The drugmakers are gearing up to manufacture the commercial supply of the antibodies through a recently announced contract with Biogen.

While the preclinical data looks promising, investors should keep in mind that Vir isn't the only company working on this antibody strategy. Eli Lilly (LLY 1.17%) has already started a clinical trial for its coronavirus-targeting antibody, LY-CoV555. And antibody-powerhouse Regeneron Pharmaceuticals (REGN 1.30%) is also developing a COVID-19 treatment with a cocktail of antibodies.

Brian Orelli has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Biogen. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Vir Biotechnology, Inc. Stock Quote
Vir Biotechnology, Inc.
VIR
$18.75 (2.68%) $0.49
GSK Stock Quote
GSK
GSK
$28.66 (-0.56%) $0.16
Eli Lilly and Company Stock Quote
Eli Lilly and Company
LLY
$311.10 (1.17%) $3.60
Regeneron Pharmaceuticals, Inc. Stock Quote
Regeneron Pharmaceuticals, Inc.
REGN
$695.01 (1.30%) $8.91

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
327%
 
S&P 500 Returns
105%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.